APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Aequitas: ECM Weekly (19 January 2026)- Montage, Eastroc, Longcheer, Busy Ming, Sunway, Amagi, Wuxi

Aequitas ECM Weekly (26 January 2026)- Busy Ming, Montage, Eastroc, Muyuan, Longcheer, Sinotruk,

Aequitas: Muyuan Foods A/H Listing - Decent Pricing, Weak Momentum

Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain

Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey

CATL A/H Trading - Strong Demand, Upsized, Included in Short-Sell List

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>WuXi Biologics Holdings is looking to raise US$460m from a partial selldown of its stake in <a href="https://www.smartkarma.com/entities/wuxi-apptec" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (2269 HK)</a>.</li>
<li>WuXi Biologics Holdings had been continuously selling down its stake over the last few years.  </li>
<li>In this note, we will talk about the placement and run the deal through our ECM framework.</li>
</ul>


WuXi Biologics Holdings is looking to raise US$460m from a partial selldown of its stake in Wuxi Biologics (2269 HK).
WuXi Biologics Holdings had been continuously selling down its stake over the last few years.  
In this note, we will talk about the placement and run the deal through our ECM framework.


Wuxi Biologics Placement: Recent Deals Haven’t Done as Well